ATE497392T1 - Therapie mit anti-cd4-antikörpern und bestrahlung - Google Patents

Therapie mit anti-cd4-antikörpern und bestrahlung

Info

Publication number
ATE497392T1
ATE497392T1 AT06761865T AT06761865T ATE497392T1 AT E497392 T1 ATE497392 T1 AT E497392T1 AT 06761865 T AT06761865 T AT 06761865T AT 06761865 T AT06761865 T AT 06761865T AT E497392 T1 ATE497392 T1 AT E497392T1
Authority
AT
Austria
Prior art keywords
radiation
antibodies
therapy
treatment
radiation treatment
Prior art date
Application number
AT06761865T
Other languages
English (en)
Inventor
Paul Parren
Ole Baadsgaard
Denis Alexander
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE497392(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab As filed Critical Genmab As
Application granted granted Critical
Publication of ATE497392T1 publication Critical patent/ATE497392T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AT06761865T 2005-08-18 2006-08-18 Therapie mit anti-cd4-antikörpern und bestrahlung ATE497392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70994305P 2005-08-18 2005-08-18
PCT/DK2006/000454 WO2007019865A2 (en) 2005-08-18 2006-08-18 Therapy with cd4 binding peptides and radiation

Publications (1)

Publication Number Publication Date
ATE497392T1 true ATE497392T1 (de) 2011-02-15

Family

ID=37714440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06761865T ATE497392T1 (de) 2005-08-18 2006-08-18 Therapie mit anti-cd4-antikörpern und bestrahlung

Country Status (12)

Country Link
US (1) US9309315B2 (de)
EP (1) EP1951303B1 (de)
JP (1) JP5230420B2 (de)
KR (1) KR20080039999A (de)
CN (1) CN101287493A (de)
AT (1) ATE497392T1 (de)
AU (1) AU2006281803B9 (de)
CA (1) CA2619695A1 (de)
DE (1) DE602006019977D1 (de)
IL (1) IL189452A0 (de)
NZ (2) NZ594784A (de)
WO (1) WO2007019865A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190627A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
CN102027017A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
JP5795167B2 (ja) 2008-03-13 2015-10-14 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
JP5013561B2 (ja) * 2009-09-24 2012-08-29 国立大学法人北海道大学 スフィンゴミエリン合成酵素ｓｍｓ２の生理機能を応用したメタボリックシンドローム改善，又は改善薬のスクリーニング方法
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
CN101879159B (zh) * 2010-04-15 2011-11-30 浙江大学 3,5-二甲基补骨脂素在制备抗肿瘤药物中的应用
US9636381B2 (en) * 2012-01-18 2017-05-02 Neumedicines, Inc. Methods for radiation protection by administering IL-12
EP3000478A4 (de) 2013-05-23 2017-03-15 IDAC Theranostics, Inc. Therapeutischer oder prophylaktischer wirkstoff gegen immundefizienzvirusinfektion
EP3838904A1 (de) * 2014-06-19 2021-06-23 Immunolight, LLC Verfahren und systeme zur behandlung von zellproliferationskrankheiten mit psoralenderivaten
CN109407133B (zh) * 2017-08-18 2023-09-22 南京中硼联康医疗科技有限公司 生物剂量计及具有其的中子捕获治疗系统
CN113840912A (zh) * 2019-05-16 2021-12-24 南京传奇生物科技有限公司 包含识别分子的工程化免疫细胞
AU2022325367A1 (en) * 2021-08-10 2024-02-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfonamide derivative, preparation method therefor and medical use thereof
CN115300500A (zh) * 2022-09-19 2022-11-08 昆明医科大学 补骨脂素在人皮肤t细胞淋巴瘤治疗药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4204244A (en) 1978-01-23 1980-05-20 Motorola, Inc. Electromechanical pressure transducer
IT1165797B (it) * 1982-10-18 1987-04-29 Consiglio Nazionale Ricerche Procedimento di preparazione di alchilangelicine esenti da psoraleni ed alchilangolicine ottenute col procedimento
DK507185A (da) * 1984-11-05 1986-05-06 Du Pont Fremgangsmaade til inaktivering af human tumor leukaemi virus iii
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US6511665B1 (en) 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2230759C (en) 1995-08-29 2012-02-21 Kirin Beer Kabushiki Kaisha Chimeric animal and method for producing the same
JP2004502742A (ja) 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
AU2002254234A1 (en) * 2001-03-14 2002-09-24 Centocor, Inc. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses

Also Published As

Publication number Publication date
US9309315B2 (en) 2016-04-12
NZ594784A (en) 2013-06-28
DE602006019977D1 (de) 2011-03-17
JP2009504690A (ja) 2009-02-05
AU2006281803B2 (en) 2013-01-24
WO2007019865A3 (en) 2007-05-18
AU2006281803A1 (en) 2007-02-22
CN101287493A (zh) 2008-10-15
JP5230420B2 (ja) 2013-07-10
NZ566520A (en) 2012-03-30
WO2007019865A2 (en) 2007-02-22
EP1951303A2 (de) 2008-08-06
CA2619695A1 (en) 2007-02-22
EP1951303B1 (de) 2011-02-02
AU2006281803B9 (en) 2013-05-30
KR20080039999A (ko) 2008-05-07
US20100015134A1 (en) 2010-01-21
IL189452A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
UA109633C2 (uk) Антитіло людини проти тканинного фактора
BE2021C505I2 (de)
AU2018256498A1 (en) Antibodies to amyloid beta
NZ705848A (en) Anti-cd38 antibodies
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
TW200510459A (en) RG1 antibodies and uses thereof
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
EA200702193A1 (ru) Гликозилирование белков
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties